Ochsner MD Anderson Cancer Center at The Gayle and Tom Benson Cancer Center in New Orleans announces a milestone in advanced ...

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, ...

Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared ...

How innovative technologies like AI and gene editing are advancing rare disease drug discovery and development.

Retatrutide helped trial participants lose up to 28.7% of their body weight, but experts warn about excessive weight loss.

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced an expansion of its collaboration with The University of Texas MD ...

The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.

NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal ...

Merck and Mayo Clinic are partnering to use AI technology and large-scale clinical data to speed drug development in MS and other conditions.

The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...

The results of 2 recent clinical trials combining the GLP-1 drug and the biologic reinforce the benefits of treating obesity and inflammation together.

Some patients with a common type of stroke benefit from a clot-busting drug given between 4.5 and 24 hours after symptoms emerged, according to a new study.